PDS Biotechnology Executive Compensation (FY25)
PDSB · Executive and director compensation, fiscal 2024 to 2025
Chief executive, fiscal 2025 ◇ Frank Bedu-Addo |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on PDS Biotechnology
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Data as of November 4, 2026Latest filing (DEF 14A): June 26, 2026
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
67 figures on this page, cited to the filing that reported them. See the citations
More on PDS Biotechnology
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is PDS Biotechnology's chief executive and what were they paid?
Frank Bedu-Addo, Chief Executive Officer, received $828,307 in total compensation for fiscal 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Frank Bedu-Addo Chief Executive Officer | ◇ | — | — | ◇ | — | — | ◇ | — not reconciled |
Kirk Shepard Chief Medical Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Stephan Toutain Chief Operating Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Frank Bedu-Addo Chief Executive Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Kirk Shepard Chief Medical Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Stephan Toutain Chief Operating Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Frank Bedu-Addo | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Kirk Shepard | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Stephan Toutain | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Frank Bedu-Addo | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | February 28, 2034 | |
| Option | ◇ | — | ◇ | June 12, 2035 | |
| Option | ◇ | — | ◇ | January 5, 2033 | |
| Option | ◇ | — | ◇ | January 19, 2022 | |
| Stephan Toutain | Option | ◇ | — | ◇ | June 12, 2035 |
| Option | ◇ | — | ◇ | May 24, 2034 | |
| RSU | ◇ | ◇ | — | — | |
| Kirk Shepard | Option | ◇ | — | ◇ | June 12, 2035 |
| Option | ◇ | — | ◇ | January 22, 2034 | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Frank Bedu-Addo (Chief Executive Officer), FY2025 total compensation $828,307 (base salary $615,322) [exec_comp, SEC accession 0001140361-26-026564, filed 2026-06-26]What this page does not include
Everything above is a fact PDS Biotechnology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
67 figures on this page, cited to the filing that reported them.
67 cited to the filing
Documents cited
- 0001140361-26-026564
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “PDS Biotechnology executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/PDSB (accessed 2026).
Short form: data: Velarion
The paid brief for PDS Biotechnology
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about PDS Biotechnology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}